EyePoint Pharmaceuticals (NASDAQ:EYPT) has received varied analyst ratings over the past quarter, with a recent shift towards more bullish perspectives. In the last 30 days, 2 bullish ratings were added, contrasting with the previous months' single bullish stance. Analysts have adjusted their 12-month price targets, resulting in an average target of $32.5, down from $35.25. The company's financial performance shows significant revenue growth but challenges in net margin, ROE, and ROA, alongside a conservative debt management approach.